The march toward digital-only payments among young Americans proceeds unabated - and is gaining momentum.
Social network users have increased from 1.4 billion in 2012 to 2.3 billion in 2016, and that growth is likely to continue.
Investors appear content to leave their money in a market that is pushing all-time highs.
Financial industry experts don't want you taking the 'friend' route with your broker or adviser and here's why.
As more and more sales shift to e-commerce, governments are looking for their cut, too. Google Fiber enters Salt Lake City.
Google Wallet sets up automatic transfers, while Tesla and SolarCity gain regulatory approval for the former to acquire the latter.
The famed investor sees great potential in energy company Phillips 66 and tech giant Apple.
The Scandanavian hit reaches Netflix.
The trial is designed to demonstrate how a driverless cab would operate in an urban environment.
A bombardment of advertisements is exhorting retirees to take out a reverse mortgage for income in their golden years. But it's important to understand clearly how they work.
Regardless of what happens to their stock prices, REITs may be set to break out come September.
Chinese stimulus money could be pushing up home prices everywhere, and bringing the spoils right back to China.
Existing-home sales dropped 3.2% in July to an annual rate of 5.39 million units, with the median price rising 5.3% from a year ago to $244,100.
China's second-largest insurer plans to allocate billions to international real estate. Here's how it will go about it.
Nymox will not be successful in convincing the U.S. Food and Drug Administration (or its counterpart in Europe) to approve fexapotide to treat men with enlarged prostates.
An Amgen drug to treat secondary hyperparathyroidism was rejected by U.S. regulators Wednesday but the biotech company offered no public explanation for why the drug's marketing application was denied.
The Nasdaq Biotechnology Index fell 3.5% heading into Wednesday's close, with the loss triggered by a statement from Clinton's presidential campaign blasting Mylan for 'outrageous' pricing of the EpiPen.
Shares of biotech micro-cap Cyclacel Pharmaceuticals have doubled in price in the past 10 days. Call it the Lloyd Christmas effect.
Acquiring Medivation will strengthen Pfizer's oncology franchise, which has lost ground in recent years to some Big Pharma competitors.
The jobs report for August, out Friday, caps off a busy week filled with crucial data, economic snapshots that will play into the Federal Reserve's decision-making later in September.
It's a 'ruly' selloff because the economy has gotten stronger and inflation is in check because of technology and globalization.
Stocks remain in the red on Friday after Federal Reserve vice chairman Stanley Fischer raises the possibility of a September hike.
How could anyone be surprised other than the jokers who bought everything at the beginning of the day?
Stocks add to gains on Friday morning after Federal Reserve Chair Janet Yellen makes the case for another rate hike.
It's a David and Goliath matchup as these two industrial goods stocks go head to head. Which one is the better bet for investors right now?
The U.S. military is spending cash hand over fist on contracts to repair and improve its fleets and munitions. Could this be the best play on this trend?
When Lockheed Martin purchased Sikorsky, many analysts scoffed. But judging by the stock's performance since the deal closed, the laugh's on them.
Intersil acquisition one of various possibilities, Renesas says.
Boeing has become increasingly dependent on its old standby, the 737, and the transformative 787 Dreamliner, a Moody's analyst says.
Living in another country can make a modest retirement account seem like a fortune, but challenges do exist.
The housing market has remained strong and credit union balances are showing solid growth.
The unpredictable nature of health care costs can be one of the most frightening of all retirement worries, regardless of your age or income.
Subprime credit cards specifically target those with terrible credit and lock them into high interest and myriad fees. Secured cards, despite a hefty deposit, are there to help.
Some partnerships between universities and boot camps offer credit as part of continuing education programs.
Pretty much every company you can think of has donated to the Clinton Foundation. So has Donald Trump. Should it matter?
Jack in the Box stock has sprung up 29% year to date. Can it continue higher?
5G, due to begin ramping around 2020, delivers improvements over 4G that should be valuable for IoT deployments. That could expand the addressable market of many chipmakers.
Earnings season is far from over, Cramer says, and the Fed chief gives a major speech Friday.
Ahead of Apple's expected iPhone 7 launches, Samsung is giving Android phablet users fresh reasons to stay loyal.
In highlights from this week's trading diary and posts, Kass tells us that the Fed has run out of credibility and describes Janet Yellen's speech as boring.
The financial services sector has been volatile lately. If you're looking for robust bank stocks to add balance to your portfolio, check out these two stable contenders.
As overhead pressure continues to increase, Disney is setting up for more downside.
Technicals indicate a major buying opportunity in Icahn Enterprises stock (IEP) is near.
Here's how to trade five stocks that are ready to break out and trade higher from current levels.